Salah Kivlighn

Dr. Salah Kivlighn's expertise spans oncology, vaccines, immuno-oncology, and cardiovascular disease treatments, including R&D, commercialization, and global market oversight for iconic brands. Salah is currently serving as CEO of HepaTx corporation. Prior to HepTx, Salah served as the Senior Vice President of Global Strategic Marketing and Program Operations for United States Pharmacopeia (USP). Before his tenure at USP, Salah served as Commercial Vice President of Kite Pharma, Inc., a subsidiary of Gilead Sciences, a cancer immunotherapy company. At Kite Pharma, Salah delivered strategic guidance and was responsible for “Focused on the Cure” branding. In this role, he defined market and differentiating product features, thus positioning the product for launch success. As Global Product Development Team Lead at MedImmune, Inc., a subsidiary of AstraZeneca, Salah and his team spearheaded the development of a Leukemia drug, LUMOXITI (moxetumomab pasudotox) which was acquired by INNATE Pharma, an independent clinical-stage biotech company. He co-led the integration of strategic marketing for the new Medi/AZ organization that resulted in a pipeline of approximately 100 programs across oncology, autoimmunity, asthma, CV, and GI, where he was accountable for the corporate strategic plan. He is a sought-after global speaker and thought leader, and he has also authored more than 77 peer-reviewed scientific publications. Salah holds a Ph.D. in Pharmacology from Texas Medical Center (University of Houston, Baylor College of Medicine & University of Texas Medical School), he completed a Fellowship in Integrated Physiology under the esteemed advisors Arthur C. Guyton and Thomas Lohmeier at the University of Mississippi Medical Center, and a Bachelor of Science in Distributed Studies from Iowa State University.